Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 41Specimen Handling 39Magnetic Resonance Spectroscopy 30Carboplatin 29Biopsy 25Cyclophosphamide 23Nivolumab 22Dexamethasone 20Gemcitabine 18fludarabine 17Bevacizumab 15atezolizumab 14Pemetrexed 13Paclitaxel 13Ipilimumab 13Docetaxel 13Cisplatin 13Temozolomide 12venetoclax 11Rituximab 11Prednisone 10X-Rays 9Injections 9Vincristine 8Oxaliplatin 8Lenalidomide 8Fluorouracil 8Cytarabine 8Capecitabine 8tocilizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × iadademstat × 30 days × Clear all
NCT06287775 2026-05-22

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡